MYOV - MYOVANT SCIENCES ()

MYOVのニュース

   The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica  2020/12/29 13:09:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Allakos Inc (NASDAQ: ALLK ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arvinas Inc (NASDAQ: ARVN ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Curis, Inc. (NASDAQ: CRIS ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) Inari Medical Inc (NASDAQ: NARI ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Lumos Pharma Inc (NASDAQ: LUMO ) Medicenna Therapeutics Corp (NASDAQ: MDNA ) Myovant Sciences Ltd (NYSE: MYOV ) - announced a licensing deal with Pfizer Inc.
   5 Top Stock Gainers for Monday: Myovant Sciences, Yelp  2020/12/28 21:24:18 The Street
Myovant Services, Yelp, Greenpro Capital, Live Oak Acquisition and Gevo.
   Why These 4 Health Care Stocks Are Moving Today  2020/12/28 19:10:48 Benzinga
Osmotica Pharmaceuticals (NASDAQ: OSMT ) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multiple sclerosis. Osmotica Pharmaceuticals is focused on developing, manufacturing and commercializing specialty products. The product portfolio of the group includes specialty neurology and women's health products, which are primarily complex formulations of generic drugs. Osmotica Pharmaceuticals shares traded up 9.18% to $5.59. The stock has a 52-week high of $9.67 and a 52-week low of $2.81. Myovant Sciences (NYSE: MYOV ) shares were trading higher after the company announced a collaboration with Pfizer in which the company will … Full story available on Benzinga.com
   Myovant shares soar 27% on news of Pfizer prostate cancer drug collaboration worth up to $4.2 billion  2020/12/28 17:01:00 MarketWatch
Shares of Myovant Sciences soared 27% Monday, after its parent Sumitovant Biopharma unveiled an agreement with Pfizer Inc. to jointly develop a treatment for…
   Deal With Pfizer Sends Myovant Shares Higher: What Investors Need To Know  2020/12/28 10:50:00 Benzinga
Myovant Sciences Ltd (NYSE: MYOV) stock is adding about one-fourth of its market capitalization Monday following a licensing deal with Pfizer Inc. …
   Myovant Sciences to Host Second Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on November 12, 2020  2020/11/02 13:30:00 GlobeNewswire
BASEL, Switzerland, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for…
   Global Cancer Care Market Latest Innovative Solutions to Boost Global Growth, Overview, Driver, Restraints, Deployments and Key Players 2027||Sanofi, Ipsen Pharma, AbbVie Inc., Myovant Sciences Ltd., Bayer AG, AstraZeneca, Tolmar Pharmaceuticals  2020/10/26 06:52:20 OpenPR
According to the latest report published by Data Bridge Market Research, the Cancer Care Market is anticipated to grow at a steady pace over the forecast period 2020 – 2027. The report sheds light on the various trends and restraining
   Correction: Financial Markets-Stocks story  2020/10/01 13:49:00 ABC News
In a story September 29, 2020, which included information about Myovant Sciences' potential prostate cancer drug, The Associated Press erroneously reported that the drug failed to meet multiple goals in a study
   Mid-Afternoon Market Update: Gold Rises 1%; Myovant Sciences Shares Plunge  2020/09/29 15:06:00 Benzinga
Toward the end of trading Tuesday, the Dow traded down 0.23% to 27520.96 while the NASDAQ fell 0.01% to 11,116.40. The S&P also fell, dropping 0.22% to …
   After a strong run, what's next for investors in Myovant Sciences?  2020/09/14 08:33:53 Stockopedia
If you've ever found yourself feeling increasingly drawn to a stock that's constantly rising in price, you are not alone…
   After a strong run, what's next for investors in Myovant Sciences?  2020/09/14 08:33:53 Stockopedia
If you've ever found yourself feeling increasingly drawn to a stock that's constantly rising in price, you are not alone…
   Myovant Sciences Announces Further Financing Support from Sumitomo Dainippon Pharma and Commercial Collaboration with Sunovion Pharmaceuticals  2020/08/05 12:30:00 GlobeNewswire
USD 200 million low-interest, five-year term loan commitment from Sumitomo Dainippon Pharma to further support planned commercialization of relugolix…
   The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact  2020/06/24 12:07:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Acceleron Pharma Inc (NASDAQ: XLRN ) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) Avidity Biosciences Inc (NASDAQ: RNA ) (went public June 12) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (went public June 12) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Crispr Therapeutics AG (NASDAQ: CRSP ) (moved on analyst action) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Dyadic International, Inc. (NASDAQ: DYAI ) Editas Medicine Inc (NASDAQ: EDIT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   Myovant's stock gains on promising endometriosis drug trial  2020/06/23 13:02:07 MarketWatch
Shares of Myovant Sciences Ltd. undefined gained 7% in premarket trading on Tuesday after the drugmaker said a late-stage clinical trial for its experimental…
   Myovant Eyes Relugolix Combo Approval for Uterine Fibroids  2020/06/02 15:44:00 Zacks Investment Research
Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix combination regimen as a treatment for heavy menstrual bleeding associated with uterine fibroids.

calendar